Dennis Giesing, a biochemical pharmacologist, brings over 30 years of translational research and development expertise participating in development programs leading to market registration in anti-infectives, allergic rhinitis, rheumatoid arthritis, cardiac arrythmias, diabetes, gastrointestinal ulcers, hypertension and overactive bladder. More recent research activities include antivirals, cancer, dyslipidemias and interstitial cystitis. Dennis has served in a variety of senior R&D roles including Sr Vice President, Lead Optimization at Aventis Pharmaceuticals where he lead translational research programs in the US, Europe and Japan. Prior to Aventis, Dennis served in leadership roles at Hoechst Marion Roussel, Marion Merrell Dow, and Marion Laboratories. After leaving large Pharma, Dennis has provided scientific and buisness development support to a number of Boston and San Francisco based early stage pharmaceutical companies. Dr. Giesing earned his PhD in Biochemical Pharmacology from the University of Missouri.